<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738188</url>
  </required_header>
  <id_info>
    <org_study_id>19229-0-02</org_study_id>
    <nct_id>NCT04738188</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;</brief_title>
  <official_title>Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria: a Multi-center, Randomized, Parallel-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, parallel controlled study to determine the efficacy and&#xD;
      safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular&#xD;
      carcinoma beyond University of California, San Francisco (UCSF) criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Downstaging success rate</measure>
    <time_frame>Within 6 months after surgery</time_frame>
    <description>Criteria for success rate in downstaging meet UCSF criteria or the standard for liver resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>1, 3, 6 months after surgery</time_frame>
    <description>Disappearance of any intratumoral arterial enhancement in all target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR)</measure>
    <time_frame>1, 3, 6 months after surgery</time_frame>
    <description>At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD)</measure>
    <time_frame>up to 6months after TACE procedure</time_frame>
    <description>Number of the subjects that do not qualify for partial response or progressive disease measured by modified Response Evaluation Criteria in Solid Tumors( mRECIST) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease (PD)</measure>
    <time_frame>1, 3, 6 months after surgery</time_frame>
    <description>An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR)</measure>
    <time_frame>1, 3, 6 months after surgery</time_frame>
    <description>CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of downstaging</measure>
    <time_frame>within 36 months</time_frame>
    <description>Interval between initial TACE treatment and the success or failure of downstaging according to the UCSF criteria assessed by the dynamic enhanced CT ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Times of TACE treatments</measure>
    <time_frame>within 36 months</time_frame>
    <description>Times of TACE surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of tumor biomarkers (AFP, PIVKA-Ⅱ)</measure>
    <time_frame>From 7 days before TACE or curative treatments to the endpoints of the trial.(Up to 36 months)</time_frame>
    <description>AFP and PIVKA-II must be measured at 1week before, 1 week,1month after TACE or curative treatment; AFP ,PIVKA-II could be measured every 3-6 months during follow up according to the availability of equipment at the site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function</measure>
    <time_frame>from the date of the first TACE to the end of the clinical trial or the death of the patient，Up to 36months</time_frame>
    <description>Changes of the Child-pugh Score that used to assess the prognosis of chronic liver disease,consisting of 5 items(ascites,total bilirubin，albumin,prothrombin time and degree of encephalopathy),of which is scored 1-3 points,with 3 indicating greatest severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-free survival (TFS)</measure>
    <time_frame>Within 36 months</time_frame>
    <description>as the time from surgery initiation to tumor recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Within 36 months</time_frame>
    <description>as the time from surgery initiation to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Within 36 months</time_frame>
    <description>as the time from surgery initiation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of Hepatocellular carcinoma</measure>
    <time_frame>Within 36 months</time_frame>
    <description>Recurrence rate of hepatocellular carcinoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Drug-eluting bead transarterial chemoembolization(DEB-TACE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional transarterial chemoembolization(cTACE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DEB-TACE</intervention_name>
    <description>Drug-eluting beads transcatheter arterial chemoembolization</description>
    <arm_group_label>Drug-eluting bead transarterial chemoembolization(DEB-TACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cTACE</intervention_name>
    <description>Transcatheter arterial chemoembolization</description>
    <arm_group_label>conventional transarterial chemoembolization(cTACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting Beads</intervention_name>
    <description>Drug-eluting beads</description>
    <arm_group_label>Drug-eluting bead transarterial chemoembolization(DEB-TACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Chemotherapy drug for intra-arterial infusion</description>
    <arm_group_label>Drug-eluting bead transarterial chemoembolization(DEB-TACE)</arm_group_label>
    <arm_group_label>conventional transarterial chemoembolization(cTACE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 70 years of age, of any sex;&#xD;
&#xD;
          2. Patients who have histopathological or cytological proof of hepatocellular carcinoma&#xD;
             (HCC) or meet the diagnostic criteria of Diagnosis, management, and treatment of&#xD;
             hepatocellular carcinoma(V2017);&#xD;
&#xD;
          3. Beyond UCSF criteria: Diameter of single HCC lesion is between 6.5 cm and 10 cm; The&#xD;
             number of tumors ≤3 with the maximum diameter of 4.5-5cm and the total diameter ≤10cm;&#xD;
             Multiple HCC lesions ≤5 nodules, each lesion diameter≤4 cm with a total diameter ≤10&#xD;
             cm. Patients cannot be treated with resection or liver transplantation;&#xD;
&#xD;
          4. Patients with stage Ib，IIa，IIb in China liver cancer staging (CNLC) ;&#xD;
&#xD;
          5. Child-Pugh's grade A or B (no more than 7 score);&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;&#xD;
&#xD;
          7. Patients with hepatitis B virus (HBV) infection should receive routine antiviral&#xD;
             therapy;&#xD;
&#xD;
          8. The function of main organs is normal and meet the following criteria:&#xD;
&#xD;
        1) Outcome of blood routine must meet the following criteria (No blood transfusion or blood&#xD;
        products were performed within 4 days, and no g-CSF or other hematopoietic stimulants were&#xD;
        used for correction): i. Hemoglobin(HB)≥90 g/L; ii. Absolute neutrophil count&#xD;
        (ANC)≥1.5×109/L； iii. Platelet (PLT)≥80×109/L; 2) Outcome of hemal biochemistry examination&#xD;
        meet the following criteria: i. Albumin (ALB) ≥29 g/L; ii. Alanine aminotransferase (ALT)&#xD;
        and aspartate aminotransferase (AST)&lt;2.5 × upper limit of normal (ULN); iii. Total&#xD;
        bilirubin (TBIL) ≤2 × ULN; iv. Serum creatinine (SCr) ≤1.25 × ULN, or endogenous creatinine&#xD;
        clearance &gt; 45 ml/min (Cockcroft-Gault formula); 3) Patients who have normal livers with an&#xD;
        Remnant Liver Volume (RLV)/Standard Liver Volume(SLV) &gt;20% ; Patients who have cirrhosis&#xD;
        with an RLV/SLV&gt;40%; 9. Life expectancy of &gt; 3 months; 10. Patients volunteered to&#xD;
        participate in this study and signed informed consent, with good compliance.Exclusion&#xD;
        Criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with extrahepatic metastasis or main portal vein /main hepatic vein invasion;&#xD;
&#xD;
          2. Patients with diffuse liver cancer;&#xD;
&#xD;
          3. Patients with myocardial ischemia, myocardial infarction or poor controlled arrhythmia&#xD;
             (including QTc≥470 ms) beyond stage Ⅱ; according to New York Heart Association (NYHA)&#xD;
             standard, patients with heart failure in stage Ⅲ～Ⅳ; patients with an left ventricular&#xD;
             ejection fraction(LVEF) &lt;50%;&#xD;
&#xD;
          4. Abnormal coagulation （International Normalized Ratio(INR)&gt;1.5, Prothrombin&#xD;
             Time(PT)&gt;ULN+4s or Activated Partial Thromboplastin Time (APTT) &gt;1.5 ×ULN）,or patients&#xD;
             with bleeding tendency or undergoing thrombolytic or anticoagulant therapy;&#xD;
&#xD;
          5. Patients unsuitable for the study in the opinion of the Investigator;&#xD;
&#xD;
          6. Pregnant or breastfeeding women; women of childbearing ages unless using effective&#xD;
             contraception;&#xD;
&#xD;
          7. Patients with mental disorders or history of abuse of psychotropic substances;&#xD;
&#xD;
          8. Infection with human immunodeficiency virus (HIV);&#xD;
&#xD;
          9. A history of liver resection, liver transplantation, interventional therapy, or&#xD;
             combined with other malignant tumors;&#xD;
&#xD;
         10. Patients with active infection;&#xD;
&#xD;
         11. Patients with contraindications to TACE or epirubicin;&#xD;
&#xD;
         12. Floating population or with poor compliance;&#xD;
&#xD;
         13. Patients in other clinical trials conducting with experimental-related drugs or&#xD;
             devices within 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiahong Dong, MD</last_name>
    <phone>01056118763</phone>
    <email>dongjiahong@mail.tsir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Chang Gung Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiahong Dong</last_name>
      <phone>13240009509</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

